Protozoan infection

A protozoan infection is a parasitic disease caused by protozoa, a diverse group of single-celled eukaryotes that includes the agents of malaria, leishmaniasis, African trypanosomiasis, Chagas disease, amoebiasis, giardiasis, trichomoniasis, toxoplasmosis and cryptosporidiosis. These organisms are distributed across the Excavata, Amoebozoa, SAR and Archaeplastida supergroups, most of them spread by insect vectors or acquired directly from contaminated water, food or surfaces. The burden is heavy: about 241 million malaria cases and 627,000 deaths were reported in 2024, and neglected tropical diseases still affect more than a billion people, with amoebiasis and leishmaniasis weighing on low-income and middle-income countries.

Terminology and classification

• The word protozoa derives from the Greek proto, meaning first, and zoon, meaning animal, and in the nineteenth century it was used for single-celled animal-like organisms, contrasting with the plant-like protophyta, and was long treated as a phylum of the animal kingdom.^[1]
• Molecular systematics has shown that protozoa are not a monophyletic group but lie scattered across several unrelated branches of the eukaryotes, sharing only superficial features such as being eukaryotic, single-celled and motile, so neither protozoa nor protists remain formal taxonomic units.^[1]
• Pathogenic protozoa are now placed in four supergroups: Excavata, Amoebozoa, SAR, and Archaeplastida, the SAR supergroup itself containing stramenopiles, alveolates and rhizaria.^[1]
• Medicine and clinical microbiology retain the broad term protozoa for morphological identification and historical reasons, and laboratory reports usually describe trophozoites, cysts and flagella by morphology.^[1]
• Protists are an artificial assemblage of more than sixty-four thousand single-celled life forms that are too diverse to define uniformly, and their polyphyletic nature means they cannot be assigned to a single taxon.^[1]
• The World Health Organization ICD-10 assigns codes by pathogen: malaria B50 to B54, amoebiasis A06, giardiasis A07.1, cryptosporidiosis A07.2, trichomoniasis A59, leishmaniasis B55, African trypanosomiasis B56, Chagas disease B57 and toxoplasmosis B58.^[2]
• ICD-11 gathers parasitic diseases in the chapter on infectious diseases, grouped by protozoa, helminths and ectoparasites, and cross-version conversion must use the official mapping rather than the shape of the code.^[2]
• MeSH indexes the individual diseases with dedicated terms such as malaria D008288, amoebiasis D000562, leishmaniasis D007896, Chagas disease D014352, toxoplasmosis D014123 and giardiasis D005873, and searching with the broad term alone should be avoided.^[1]
• Protothecosis is caused by Prototheca, a green alga that lacks chlorophyll and has become parasitic, and although not strictly a protozoan it is often discussed alongside protozoan infections and mainly affects cattle and dogs.^[3]
• This group is not a single disease entity but a category aggregated by pathogen, and the terminology section should state that it covers many conditions with different causes, mechanisms and courses rather than one infection.^[1]
• The clinical term protozoal infection is too broad, merging the periodic fever of malaria, the intestinal ulcers of amoebiasis and the neurological disease of trypanosomiasis, and formal reports should name the genus and species and the site of infection.
• A distinction must be drawn between infection and colonisation, because organisms such as Dientamoeba fragilis may persist in the gut without symptoms and cause disease only under certain conditions, so a positive result does not equal active infection.^[2]
• Rhizarian examples such as Plasmodiophora and Marteilia infect crops and oysters respectively, showing that protozoan infections are not restricted to humans and that cross-host comparison helps explain pathogenesis.^[1]
• In translation the Chinese terms protozoa and protozoon are used interchangeably, and search strategies should cover both renderings to avoid losing records.
• The group is often folded into the broader concepts of parasitic disease and neglected tropical disease in travel medicine, and cross-database alignment should preserve the original pathogen name to avoid losing meaning.

History

• In 1674 the Dutch scholar Leeuwenhoek first observed free-living protozoa with a self-made microscope, opening the era of studying single-celled eukaryotes microscopically and laying the foundation for understanding parasitic disease.
• In 1880 the French army surgeon Laveran found malaria parasites in the blood of patients in Algeria and received the Nobel Prize in 1907, linking malaria to an observable pathogen for the first time.^[4]
• In 1897 the British physician Ronald Ross dissected anopheline mosquitoes in India and found the developmental stages of the malaria parasite, proving that mosquitoes transmit malaria, a discovery recognised with the Nobel Prize in 1902.^[5]
• In 1898 Grassi and colleagues in Italy confirmed that human malaria is transmitted by anopheline mosquitoes, corroborating the vector theory of disease alongside work on avian malaria.^[5]
• Through the late nineteenth and early twentieth centuries Leuckart and Manson turned tropical medicine from an empirical into an experimental discipline, with colonial health needs as a major external driver of that shift.^[6]
• Around 1911 investigators distinguished the pathogenic Entamoeba histolytica from the commensal Entamoeba coli, clarifying the boundary between amoeba carriers and amoebic dysentery.
• In the mid-twentieth century chloroquine and metronidazole became available and gave effective drugs for malaria and protozoal diarrhoea, although resistance emerged as their use spread.
• In the 1960s and 1970s African trypanosomiasis and Chagas disease persisted in resource-limited regions and prompted the World Health Organization to strengthen surveillance and control of parasitic disease.
• In 1975 the UNDP, the World Bank, the World Health Organization and UNICEF jointly funded the Special Programme for Research and Training in Tropical Diseases, redirecting research towards poverty-related infections.^[7]
• In the 1990s molecular and immunological methods entered practice and polymerase chain reaction and enzyme-linked immunosorbent assay gradually supplemented microscopy, markedly improving detection of low-load infection.^[2]
• After 2000 artemisinin-based combination therapy became first-line for falciparum malaria, and neglected tropical diseases were redefined as preventable and controllable public health problems with much larger control resources.^[7]
• Over the last two decades genome sequencing revealed the antigenic variation of malaria parasites and trypanosomes, explaining why a single vaccine fails and driving work on multivalent and broad-spectrum vaccines.
• Recent work links climate warming to the geographic spread of protozoan infection, with malaria and neglected tropical diseases extending to higher altitudes and latitudes.^[8]
• A major overturned hypothesis was the miasma theory, which long attributed malaria to bad air from swamps until mosquito transmission was proved.^[9]

Epidemiology

• In 2024 about 241 million malaria cases and 627,000 deaths were reported worldwide, children under five accounted for most deaths, and sub-Saharan Africa carried more than ninety percent of the burden.^[8]
• Neglected tropical diseases together affect more than a billion people, and scabies, schistosomiasis and lymphatic filariasis overlap with protozoan infections in poor regions, producing combined health and economic burdens.^[7]
• Leishmaniasis is estimated at four to twelve million prevalent cases, with new visceral cases concentrated in India, East Africa and South America and cutaneous forms widely distributed around the Mediterranean, the Middle East and Central Asia.^[10]
• Chagas disease is estimated at about 6.2 million infections in the Americas in 2017 and causes about 7,900 deaths a year, mainly in poor rural areas of South and Central America.^[7]
• African trypanosomiasis caused about 11,000 reported cases in 2015, is almost uniformly fatal without treatment, and reported numbers have fallen markedly over the past two decades because of control efforts.^[7]
• Amoebiasis is the third leading cause of death from parasitic disease and is common in tropical and subtropical regions with poor sanitation, with about one in ten infected people developing invasive disease.^[11]
• Giardiasis and cryptosporidiosis are major causes of waterborne diarrhoea, and Cryptosporidium resists chlorination and often causes large outbreaks when municipal water is contaminated.^[12]
• Toxoplasmosis is globally distributed and an estimated sixty million people carry it in the United States alone, mostly as asymptomatic latent infection, with immunocompromised people and fetuses at high risk.^[7]
• The distribution of these infections tracks climate, vector density and sanitation, and year-round heat and rain in the tropics raise breeding sites and vector abundance and lengthen the transmission season.^[8]
• Risk factors include at least lack of safe water and sanitation, housing without bed nets or screens, contact with contaminated soil or undercooked meat, immunosuppressive therapy and travel or migration to endemic areas.^[12]
• Socioeconomic status is the most important macrolevel risk factor, because poverty limits access to care and protection and malnutrition and co-infection further weaken resistance.^[7]
• Sex and occupation also shape exposure, as farmers, fishers and forest workers meet vectors and contaminated water more often, and pregnant women suffer worse outcomes in malaria and toxoplasmosis.
• Migration and urbanisation are changing the disease spectrum, as population movement brings Chagas disease and visceral leishmaniasis into non-endemic cities and poses new challenges for blood-bank screening and clinical recognition.
• Climate change is raising the altitude and latitude suitable for vectors and altering rainfall that shapes breeding sites, and long-term monitoring shows geographic expansion of several vector-borne protozoan infections.^[8]
• For data sources the WHO world malaria report, the neglected tropical disease roadmap and national surveillance are the main counts, and prevalence and incidence under different definitions cannot be compared directly.^[8]

Pathophysiology

• Protozoa are single-celled eukaryotes with a plasma membrane, also called a cytoplasmic membrane, and internal cytoplasm, and some have a pellicle below the membrane that gives support and protection.^[1]
• Two types of vacuoles are common, contractile vacuoles for osmoregulation and phagocytic vacuoles for taking in food, and some species have flagella or cilia that generate water currents to aid movement, feeding and respiration.^[1]
• Nutrition takes at least three forms: saprozoic nutrition by enzymatic breakdown of dead organic matter, osmotrophic nutrition by absorption of soluble products, and holozoic nutrition by phagocytosis of solid particles.^[1]
• Energy metabolism differs by group, with aerobic chemoorganotrophs using mitochondria, photosynthetic forms using mitochondria and chloroplasts, and anaerobic chemoorganotrophs using hydrogenosomes that release molecular hydrogen.^[1]
• Encystation is the formation of a walled dormant cyst with reduced complexity and metabolic activity that protects against environmental change, serves as a site for nuclear reorganisation and cell division and can carry parasites to new hosts, and excystation restores the original state.^[2]
• Cysts of Entamoeba histolytica reach the terminal ileum and excyst into trophozoites that invade the colonic mucosa, producing ulcers, perforating the bowel and forming abscesses in the liver, lung and brain.^[2]
• Reproduction is asexual or sexual, asexual forms dividing by binary fission, multiple fission, budding and fragmentation and sexual forms by conjugation through gamete fusion, termed autogamy within one individual and conjugation between individuals.^[1]
• Immune evasion is central to pathogenesis, because trypanosomes and malaria parasites evade immune recognition by frequent variation of surface antigens, preventing durable protective immunity and hampering vaccine development.^[10]
• Mechanisms differ by pathogen, with malaria parasites multiplying inside red cells to cause haemolysis and microvascular obstruction, amoebae adhering and lysing host cells through galactose-binding lectins, and trypanosomes invading nerve and heart tissue.^[11]
• Host inflammation both defends and harms, and excessive cytokine release can worsen cerebral malaria and myocardial damage, while immunosuppressed people progress more readily to disseminated disease.
• Vector and host specificity shape the disease spectrum, with Anopheles transmitting human malaria, sandflies transmitting Leishmania, tsetse flies transmitting African trypanosomes and triatomine bugs transmitting Trypanosoma cruzi, so vector geography limits endemic areas.^[10]
• Immune status affects outcome, and pregnancy, childhood and human immunodeficiency virus infection predispose to severe disease, indicating a central role for cellular immunity in control.
• Chronic infection causes long-term pathology, with chronic Chagas disease marked by cardiac dilatation and gut dilation and chronic schistosomiasis linked to bladder cancer and liver fibrosis.^[7]
• Co-infection and nutrition modify the course, with malaria and malnutrition aggravating each other and intestinal protozoan co-infection common in children with poor sanitation.^[12]

Clinical features

• Malaria produces periodic chills, high fever and sweating with anaemia and hepatosplenomegaly, children may develop cerebral malaria with convulsions, coma and death, and falciparum malaria can progress rapidly.^[8]
• Amoebiasis features bloody and mucoid diarrhoea that may alternate with constipation and remission, with abdominal pain and fever, and severe cases form amoeboma, fulminant colitis and toxic megacolon.^[11]
• Cutaneous leishmaniasis produces crusted ulcers weeks after a bite, while visceral leishmaniasis involves liver, spleen and bone marrow with fever, anaemia and hepatosplenomegaly and is fatal untreated.^[10]
• African trypanosomiasis has two stages, the first with fever, headache, pruritus and arthralgia and the second with insomnia, confusion, ataxia and hemiparesis, which can end in death within one to three years.^[7]
• Chagas disease is occult or mild in the acute phase and in the chronic phase causes cardiac dilatation, heart failure and oesophageal and colonic dilation, making it a leading cause of heart failure in South America.^[7]
• Giardiasis presents with watery diarrhoea, bloating and steatorrhoea, and children may show growth retardation, with infection often linked to contaminated water.^[12]
• Toxoplasmosis is usually asymptomatic in immunocompetent people, congenital infection can damage the fetal brain, eyes and other organs, and immunocompromised people may develop fatal encephalitis.^[7]
• Cryptosporidiosis causes watery diarrhoea that is self-limiting in immunocompetent people but prolonged and dehydrating in the immunocompromised.^[12]
• Complications include at least haemolytic anaemia and acute kidney injury, bowel perforation and diffuse peritonitis, liver and lung abscesses, myocarditis and heart failure and neurological sequelae, and severe cases die from multi-organ involvement.^[11]
• Among special populations, children under five, pregnant women and immunocompromised people are at high risk of severe disease, and malaria and toxoplasmosis in pregnancy can cause miscarriage, preterm birth and neonatal infection.^[8]
• Onset varies, with malaria attacks periodic, amoebiasis insidious and then progressive, and leishmaniasis dividing into localised cutaneous and disseminated visceral forms.
• Duration depends on pathogen and immune status, with untreated visceral leishmaniasis fatal within months to two years and chronic Chagas disease silent for decades before cardiac symptoms appear.
• On examination splenomegaly occurs in malaria and visceral leishmaniasis, jaundice and anaemia suggest haemolysis or liver injury, and lymphadenopathy is common in disseminated infection.
• Fever patterns differ by pathogen, with vivax and ovale malaria recurring every forty-eight hours, quartan malaria every seventy-two hours and falciparum malaria irregular and more dangerous.

Diagnosis

• Microscopy remains the basis for many protozoan infections, with Giemsa or Wright staining of peripheral blood to find malaria parasites and wet mounts or iodine staining of stool to identify amoebic and giardial cysts or trophozoites.^[2]
• Enzyme-linked immunosorbent assay detects antibody or antigen, supports the diagnosis of giardiasis and is sensitive for anti-parasitic antibody in visceral leishmaniasis.^[10]
• Polymerase chain reaction is highly sensitive and can detect malaria, trypanosome and Toxoplasma nucleic acid at low load or when microscopy is negative, and is becoming important for surveillance and treatment monitoring.^[2]
• Malaria diagnosis combines thick and thin films with rapid antigen tests, and falciparum malaria requires assessment of parasite density and of signs of cerebral involvement to guide emergency treatment.^[8]
• Amoebiasis is diagnosed by stool examination, extraintestinal disease can be supported by imaging and serology, and aspiration of a liver abscess can provide parasitological proof.^[11]
• Chagas disease is confirmed by physical examination with blood testing, with direct microscopy of trypanosomes in the acute phase and serology in the chronic phase, requiring two different methods for agreement.^[7]
• Toxoplasmosis is diagnosed by serology and polymerase chain reaction, acute infection in pregnancy requires assessment of mother-to-child transmission risk, and imaging may show cerebral calcification and chorioretinitis.^[7]
• Differential diagnosis includes at least bacillary dysentery and typhoid, viral hepatitis and viral diarrhoea, tuberculosis and lymphoma causing hepatosplenomegaly, autoimmune haemolysis and other causes of central nervous system infection.^[11]
• Diagnostic delay is common where resources are limited, because microscopy depends on experience and equipment, low parasite density is easily missed, and molecular testing is sensitive but costly and not routinely available.^[2]
• Screening differs by population, with pregnant women and blood donors often screened for malaria, Chagas disease and toxoplasmosis and migrants and refugees benefiting from targeted parasitological testing.^[7]
• Specimen choice affects yield, so malaria blood should be taken during fever with thick and thin films, stool should be sampled repeatedly for intestinal protozoa and bone marrow or splenic aspirate taken for visceral leishmaniasis.^[2]
• Treatment monitoring requires repeat testing, because falling parasite density and clinical improvement are not always synchronous, and molecular testing helps identify relapse and recrudescence.^[7]

Management

• Treatment aims to clear the pathogen, relieve symptoms, interrupt transmission and prevent relapse, and the regimen depends on the genus and species, the site of infection, host immunity and local resistance.^[7]
• Malaria is treated first-line with artemisinin-based combination therapy, severe and cerebral malaria with intravenous artesunate, and vivax and ovale malaria with added primaquine to clear hepatic hypnozoites.^[8]
• Amoebiasis is treated with nitroimidazoles, including metronidazole, tinidazole, ornidazole, secnidazole and chloroquine in different settings, with nitazoxanide and paromomycin also having a role.^[13]
• Tinidazole is effective in childhood amoebiasis and sequential luminal amoebicides reduce relapse, but conventional therapy has marked side effects and its effectiveness is threatened by resistance.^[13]
• Visceral leishmaniasis can be treated with amphotericin B approved by the United States Food and Drug Administration and cutaneous and mucosal forms with oral miltefosine, which are important named therapies.^[10]
• African trypanosomiasis is treated by stage, with suramin and pentamidine for the first stage and eflornithine or melarsoprol for the second, the latter used cautiously because of toxicity.^[7]
• Chagas disease can be treated in the acute and chronic phases with benznidazole or nifurtimox, drugs supplied by the Centers for Disease Control and Prevention rather than routinely approved.^[7]
• Toxoplasmosis is treated with pyrimethamine and sulfadiazine together with folinic acid to reduce marrow suppression, and pregnancy and immunosuppression need specialist assessment and long-term maintenance.^[7]
• Giardiasis and cryptosporidiosis can be treated with nitroimidazoles and nitazoxanide respectively, and because Cryptosporidium resists chlorination severe cases rely on fluid and nutritional support.^[12]
• Non-drug care includes fluids, correction of electrolyte disturbance, nutritional support and symptomatic treatment, and severe cases need intensive monitoring and organ support.^[7]
• Prevention centres on safe water and sanitation, and handwashing and sanitation alone markedly reduce childhood intestinal protozoan infection whereas chlorination and nutritional intervention alone have limited effect.^[12]
• Vector control including sleeping under bed nets, indoor residual spraying and removal of breeding sites is key to preventing malaria and leishmaniasis.^[8]
• For vaccines some malaria products with partial protection have entered use, but protection is limited and short-lived for several reasons, and most protozoan infections still lack an effective vaccine.^[7]
• Prognosis varies markedly with pathogen and with how early care is sought, since falciparum malaria and visceral leishmaniasis can kill quickly when treatment is delayed while timely standard treatment cures most patients and reduces transmission.^[8]

Research and controversies

• Therapeutic research is turning to channels and transporters that protozoa need for survival, seeking new antiprotozoal targets to circumvent resistance to existing drugs.^[14]
• The link between the individual microbiome and susceptibility to protozoan infection is an emerging direction, with gut flora possibly affecting host resistance to Giardia and amoebae.^[15]
• Drug resistance is a long-standing controversy, as malaria parasites resist several antimalarials and amoebae and trypanosomes show declining efficacy, prompting combination and rotation strategies.^[13]
• The vaccine dilemma stems from antigenic variation, because trypanosomes and malaria parasites frequently change surface antigens, so finding conserved targets among shifting antigens remains unresolved.^[10]
• Diagnostic access is contested, since molecular tests are sensitive but expensive and microscopy is cheap but experience-dependent, and the gap in access where resources are limited directly causes underestimation of burden.^[2]
• The role of climate change is debated, with most studies supporting warming-related expansion of vector habitat and longer transmission seasons but with quantitative effects on specific diseases and regions still uncertain.^[8]
• Overdiagnosis and underdiagnosis coexist, because a positive result in an asymptomatic carrier may lead to unnecessary treatment while low-load infection is often missed, making diagnostic thresholds a focus of dispute.^[2]
• Unmet needs include low-cost sensitive field tests, broad-spectrum antiparasitic drugs, vaccines covering several pathogens and affordable treatments for poor populations.^[7]
• Divergent definitions make cross-study comparison difficult, since prevalence, incidence and case fatality are often conflated and underreporting in some countries biases global estimates.^[8]
• Environmental and ecological perspectives are entering the debate, and the impact of vector control on non-target organisms, insecticide resistance and ecological balance require balancing disease control against environmental protection.